|Bid||6.28 x 1800|
|Ask||7.09 x 1200|
|Day's Range||6.66 - 7.16|
|52 Week Range||6.28 - 33.97|
|Beta (5Y Monthly)||0.97|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for AUPH
In this piece, we will take a look at the ten stocks to sell now according to Orkun Kilic’s Berry Street Capital. If you want to skip our introduction of the hedge fund and jump ahead to the top five stocks in this list, then head on over to 5 Stocks to Sell Now According […]
Aurinia Pharmaceutical (AUPH) receives marketing authorization from the European Union for its orally administered CNI immunosuppressant, Lupkynis, for treating lupus nephritis.
To get a sense of who is truly in control of Aurinia Pharmaceuticals Inc. ( NASDAQ:AUPH ), it is important to...